ECCO 2022

Combination trials open a new door in IBD treatment

Combined endpoints as new therapy goals

The potential of histology in Crohn´s disease and how AI will contribute

Microbiota manipulation: Still a lot to learn

Light at the end of the Pouchitis track

Is the continuation of combination therapy the key to success in CD?

The interleukin-17 conundrum

Withdrawal of infliximab or anti-metabolite therapy in CD in sustained remission

When to withdraw therapy in crohn's disease?

Combination of biologics - finally arrived in IBD!?

Combination with different classes of drugs in moderate to severe UC

Proactive TDM or SOC for monitoring infliximab treatment in immun-mediated patients?

SPARE study in ECCO 2022

Infliximab withdrawl leeds to a higher risk of (reversible) relapse in Crohn's disease

Is the speedity of the steroid tapering important during initiation of infliximab?

How to deescalate treatment in CD?

Combination of biologics

Ustekinumab for fistulizing disease

FMT is not a promising option for UC patients

Will we improve the management of IBD by combining biologics?

FMT in UC - still far away from the success story

Filgotinib for fistulizing disease

Is stopping of therapy an option in CD?

A negative control trial for FMT in UC

The first combination therapy trial

Proactive TDM

A new opportunity for proactive TDM disease control

Du nouveau sur l’allégement thérapeutique au cours de la maladie de Crohn

Das Interleukin-17 Rätsel

Wann Beendigung von Infliximab oder Immunmodulatoren bei M. Crohn?

Una nuova opportunità per i TDM nel controllo proattivo di malattia

Ist der Therapiestopp eine Option in CD?

Allons nous améliorer la prise en charge des MICI en combinant les traitements biologiques?

מחקר SPARE ב ECCO 2022

Προληπτική μέτρηση των θεραπευτικών επιπέδων του φαρμάκου (TDM) ή κλασική παρακολούθηση της θεραπείας με infliximab σε ασθενείς με ανοσιακά νοσήματα

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την αποτελεσματικότητα της θεραπείας με infliximab

FMT ist kein vielversprechender Ansatz für UC-Patienten

Un essai négatif sur la transplantation de microbiote dans la RCH

Combinazione di biologici

Il primo trial di terapia biologica di combinazione

Kombination von Biologika - endlich bei IBD angekommen!?

FMT w colitis ulcerosa - wciąż daleko od sukcesu

Is combination therapy safe?

Can we translate rheumatoid arthritis to ulcerative colitis?

Inflammatory bowel disease and cancer risk

COVID-19: still a moving target!

Which IBD patients have a higher risk of safety concerns?

The heart is apparently safe with continuous Ozanimod treatment

A touch of the near future in IBD treatment

Breastmilk is tuning IBD risk

Muttermilch beeinflusst das IBD-Risiko

Il cuore sembra essere apparentemente al sicuro durante il trattamento continuativo con ozanimod

Uno sguardo al prossimo futuro nel trattamento delle IBD

Fistulizing Crohn‘s disease - new treatment options with JAKis and IL-12/IL-23 inhibition

The race is on IL-23 – exciting data for CD and UC

Efficacy update on JAKis

Mucosal healing: Will efficacy data translate into real world?

Vedolizumab: promising data for pouchitis and IBD in children

Great news on pouchitis treatment - vedolizumab effective

New opportunity in pouchitis treatment

New ways of treatment

Upadacitinib - will it be the game changer in UC?

Guselkumab as maintenace treatment in Crohn's Disease

Vedolizumab is effective in chronic pouchitis after IPAA for UC

JAK inhibition

Anti-IL-23 - a turning point?

Vedolizumab in chronic pouchitis - a new chapter in therapeutic algorithms?

Selective IL-23 blockade

JAK-Inhibition

Selektive IL-23 Blockade

Upadacitinib - nowy lek, duże nadzieje

Nuevos caminos en el tratamiento

Anti-IL-23 - eine Zeitenwende?

Wedolizumab w pouchitis - początek nowego rozdziału w terapii?

Una nuova opportunità nel trattamemto della pouchite

Guselkumab come terapia di mantenimento

Patient relevant outcomes also show efficacy of upadacitinib in UC

New therapy goals: urgency and disease clearance

New therapeutic goals in UC

Disease control is possible!

Histological findings in mirikizumab treatment

Natural history of anal ulcerations in pediatric-onset CD

New goals for IBD

Histoire naturelle de la maladie de Crohn ano-périnéale pédiatrique

Nuevas objetivos en las EII

Disease Control ist möglich!

Urgency und Disease Clearance

The efficacy of COVID-19 vaccines in IBD - what's new?

COVID-19 in patients with IBD stratified acc. to therapy

תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי דלקתיות מרובדים לפי טיפול

Skuteczność szczepień przeciw COVID-19 w IBD - nowe dane

Point of Care Testing / AI / Telemedicine

Ultrasound as a predictor of treatment response

Ultraschall als Prädiktor des Therapieansprechens

Digitale Tools, KI und Telemedizin

ECCO guidelines on pregnancy

Spanish women leading contribution to ECCO 2022

Las mujeres lideran la contribución española a la ECCO 2022

ECCO Richtlijnen zwangerschap